



(51) International Patent Classification:
A61K 31/683 (2006.01) *A61P 9/00* (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:
PCT/CA2010/001720

(22) International Filing Date:
29 October 2010 (29.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/256,106 29 October 2009 (29.10.2009) US

(71) Applicant (for all designated States except US):
ACASTI PHARMA, INC. [CA/CA]; 225 Promenade Du
Centropolis, Suite 200, Laval, Quebec H7T 0B3 (CA).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **SAMPALIS, Fotini**
[CA/CA]; 1348 Elizabeth Boulevard, Laval, Quebec
H7W 3J8 (CA). **HARLAND, Henri** [CA/CA]; 139, rue
Ducharme, Rosemere, Quebec J7A 4H8 (CA).

(74) Agent: **DEETH WILLIAMS WALL LLP**; 150 York
Street, Suite 400, Toronto, Ontario M5H 3S5 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS



(57) Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.

FIGURE 1B



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

5 **CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS**

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of Provisional Application Serial No. 61/256,106, filed October 29, 2009, the contents of which are incorporated by reference in their entirety. All patents, patent applications, and publications cited herein are incorporated
10 herein by reference in their entireties.

FIELD OF THE INVENTION

[0002] The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.

15 **BACKGROUND OF THE INVENTION**

[0003] Genetic traits, coupled with a Western diet and lifestyle, have made cardiometabolic disorders / metabolic syndrome (MetS) a growing global epidemic. Cardiometabolic syndrome refers to a cluster of cardiovascular risk factors that include central obesity, high blood pressure, impaired glucose tolerance, hyperglycemia and
20 dyslipidemia. Dyslipidemia is a major modifiable risk factor leading to atherosclerotic and related cardiovascular diseases (CVD), the nation's number one killer.

Cardiovascular Disease

[0004] Cardiovascular disease affects one in three people in the United States during their lifetime, and accounts for nearly a third of the deaths that occur each year (Rosamond W, *et al.*, *Circulation*, 115, e69–e171, (2007)). Cardiovascular diseases are defined as diseases
25 which affect the heart or blood vessels

[0005] Statins are considered as first-line therapy for subjects at risk for CVD focusing predominantly on the reduction in low-density lipoprotein cholesterol (LDL-C or “bad cholesterol”), to recommended target levels. However statins have minimal effect in raising
30 high-density lipoprotein cholesterol (HDL C or “good cholesterol”), now recognized as a major risk factor for developing cardiovascular disease. Treatment options to raise HDL-C are very limited and include Niaspan® (branded niacin) which is known to cause flushing

5 and is reported to cause hepatic enzyme abnormalities, and Tricor® (branded fenofibrates) which causes a 40% increase in LDL C and significant increase in liver enzymes, hematological changes, gall stones, pancreatitis, as well as myopathy. Some treatment options lower plasma triglycerides but have a negligible effect on HDL-C (Lovaza®). Other treatment options increase HDL-C, but are less effective on triglycerides.

10 [0006] Others have tried to increase HDL C (good cholesterol) without deleteriously affecting LDL, TG, or causing hypertension, but have not been successful. For example, torcetrapib appeared to raise HDL levels, but had no effect on TGs and LDL. However, torcetrapib caused severe hypertension and high mortality in phase III trials. Despite advancements in lowering total cholesterol, lipid abnormalities as well as other severe
15 negative side effects still prevail. Treatment gaps in the management of dyslipidemia, considered one of the top five major modifiable risk factors of CVD, represent critical unmet medical needs. While most treatment methods only target the intrinsic LDL-C synthesis in the liver, other treatments are needed to further reduce triglycerides while increasing HDL-C and not increasing LDL-C.

20 *Neurodevelopmental and neurodegenerative disease*

[0007] Neurodevelopmental and neurodegenerative diseases/disorders and neurological imbalance (in neurotransmitters) affect many people, and are defined as chronic progressive neuropathy characterized by selective and generally symmetrical loss of neurons in motor, sensory, or cognitive systems. One progressive neurodegenerative disorder, Alzheimer's
25 disease (AD), is irreversible, and is characterized by gradual cognitive deterioration, changes in behavior and personality. These symptoms are related to neurochemical changes, neural death, and the breakdown of the inter-neural connections. Loss of short-term memory is often the first sign, followed by cognitive deficits involving multiple functions. Early stages of AD and mild cognitive impairment are characterized as milder forms of memory loss or
30 cognitive impairment that could precede the onset of dementia and AD. Prevention of further cognitive decline in subjects with these possible precursor conditions is of paramount importance given that reversibility of AD is not possible.

[0008] It is estimated there are currently about 5.1 million people with Alzheimer's disease (AD) in the United States (Alzheimer's Association, 2007) and this number is
35 expected to reach 13.2 million by 2050 (Hebert et al., 2003). Alzheimer's is ranked as the 7th leading cause of death in the US for people of all ages and the 5th for people aged 65 or older

5 (National Center for Health Statistics, 2004). In Canada it is 280,000 people over 65 that are estimated to have AD, and over 750,000 are expected to have the disease by 2031 (Alzheimer Society of Canada, 2006). It is estimated to 10% of all North Americans over the age of 70 years have early stage AD or mild cognitive impairment.

[0009] Alzheimer's disease is characterized by two main pathological features of the
10 brain: intracellular neurofibrillary tangles formed by abnormal protein τ (tau); and extracellular neuritic plaques formed by β -amyloid peptides ($A\beta$) (Kuo et al., 1996). The overproduction of $A\beta_{42}$ is genetically induced but environmental risk factors are required to get fully symptomatic AD (Grant et al., 2002). Among these risk factors, low docosahexaenoic acid (DHA) is one of the most important dietary risk factor for AD (Morris
15 et al., 2005). The reasons for the impact of DHA on learning and memory and the association with AD are unclear but could result from its loss in synapses (Montine et al., 2004), which are normally rich in DHA (Salem et al., 2001), where it is particularly important for postsynaptic transmission and neuroprotection (Bazan, 2003). Studies in animal models have consistently showed that brain n-3 fatty acid content is highly dependent on dietary intake
20 and aging (Favre et al., 2000; Youdim et al., 2000; Calon & Cole, 2007). However, some reports claim higher concentrations of DHA have a deleterious effect in neurological patients.

Omega-3 Fatty Acids and Inflammation

[0010] Several animal studies, has shown that increased DHA intake has been found to increase hippocampal acetylcholine levels and its derivatives, neuroprotectin D1, which
25 decreased cell death (Aid et al, 2005; Lukiw et al., 2005). A study conducted on aged mice showed that DHA intake improved memory performance (Lim et al. 2001). In another Alzheimer's disease mouse model, reduction in dietary DHA showed loss of postsynaptic proteins associated with increased oxidation, which was localized in the dendrites. However, when a group of DHA-restricted mice were given DHA, they showed signs that the DHA
30 intake protected them against dendritic pathology, implying that DHA could be useful in preventing cognitive impairment in Alzheimer's Disease (Calon et al., 2004).

[0011] Several epidemiological studies have shown a protective effect associated with increased fish intake (a direct source of omega 3 fatty acids) against dementia and cognitive impairment decline (Kalmijn et al. 1997, Barberger-Gateau et al. 2002; Morris et al 2003).
35 Recently, one large randomized double-blind placebo-controlled study found 1.6 g DHA and 0.7 EPA may be beneficial in reducing risk for AD (Freund-Levi et al, 2006). In addition,

- 5 there is mounting evidence that dietary supplementation with Omega 3 fatty acids may be beneficial in different psychiatric conditions such as mood behaviour, depression and dementia (Bourre et al., 2005; Peet and Stokes, 2005; Stoll et al., 1999).

[0012] The anti-inflammatory effects of omega-3 fatty acids have been widely studied with positive results for several chronic inflammatory diseases. C-reactive protein (CRP) is a
10 protein that increases dramatically during inflammatory processes and is commonly measured as a marker of inflammation. Greater intake of omega-3 polyunsaturated fatty acid is related to a lower prevalence of elevated CRP levels. Animal models of colitis indicate that fish oil, a natural source of omega 3 fatty acids, decreases colonic damage and inflammation. Fish oil supplements in subjects with IBD have shown to modulate levels of inflammatory mediators
15 and may be beneficial for the induction and maintenance of remission in ulcerative colitis. In the management of RA and other inflammatory conditions, side effects limit the use of NSAIDs, such as salicylates, ibuprofen and naproxen. A clinical trial showed that 39 percent of subjects with RA supplemented with cod liver oil were able to reduce their daily NSAID requirement by greater than 30 percent. Omega-3 fatty acids have been used to reduce the
20 risk for sudden death caused by cardiac arrhythmias.

[0013] Furthermore, omega-3 fatty acids have been shown to improve insulin sensitivity and glucose tolerance in normoglycemic men and in obese individuals. Omega-3 fatty acids have also been shown to improve insulin resistance in obese and non-obese subjects with an inflammatory phenotype. Lipid, glucose and insulin metabolism have been show to be
25 improved in overweight hypertensive subjects through treatment with omega-3 fatty acids.

[0014] Omega-3 fatty acids can be obtained from marine organisms such as squid, fish, krill, etc. and are sold as dietary supplements. However, the uptake of omega-3 fatty acids by the body is not efficient and these raw oils contain other substances such a triglycerides and cholesterol which are known to cause deleterious side effects such as an increase in LDL-C.
30 Certain fish oils have been developed as pharmaceutical-grade OM3-acid ethyl esters. One such OM3-acid ethyl ester is presently sold under the brand name Lovaza®. Studies have shown that Lovaza® can decrease plasma triglycerides levels in patients, however, Lovaza® has a negligible effect on raising good cholesterol (HDL-C). AMR101 is another ethyl ester

- 5 form of OM3 fatty acids based on EPA with little or no DHA that is presently in clinical trials. AMR101 also appears to decrease triglycerides but also has a negligible effect on raising HDL-C.

[0015] A phospholipid composition of OM3 fatty acids has been disclosed in US 2004/0234587. This phospholipid composition has OM3 fatty acids esterified to the
10 phospholipid. This phospholipid composition is reported to be at a concentration of about 40% phospholipids (w/w composition) and contains high concentrations of triglycerides (about 45%) and free fatty acids (about 15%). When tested in subjects, this composition demonstrated very little effect on lowering triglyceride plasma levels (less than 11% reduction).

15 [0016] Marine oil compositions comprising free fatty acids and lipids, including OM3 fatty acids and phospholipids, have been disclosed in WO 2000/23546, however the compositions do not disclose OM3 fatty acids esterified to diglycerol phosphate and have very high concentrations of triglycerides and free fatty acids, and for these reasons would not be expected to reduce triglycerides even to the level of the composition disclosed in US
20 2004/0234587, described above.


[0017] Therefore, new forms of omega-3 fatty acids are needed that are useful for treating or preventing disease. Described herein are novel concentrated therapeutic phospholipid compositions, as well as pharmaceutical compositions comprising same, and methods of their use.

25

5

SUMMARY OF THE INVENTION

[0018] Accordingly, in one aspect concentrated therapeutic phospholipid compositions are described, the compositions comprising compounds of the Formula I:



10

(I)

wherein for each compound of Formula I in the compositions


each R_1 is independently selected from hydrogen or any fatty acid;

each R_2 is independently selected from hydrogen or any fatty acid;

wherein at least one of R_1 and R_2 in each compound of Formula I is a fatty acid; and

15

each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ or



20

wherein the total amount of the compounds of Formula I in the composition being at a concentration of between 45% (w/w) to about 99% (w/w).

5 **[0019]** In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 45% (w/w (phospholipids/total composition)) up to 70% (w/w (phospholipids/total composition)). In still further embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 50% (w/w (phospholipids/total composition)) up to 70% (w/w (phospholipids/total composition)). In 10 other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 60% (w/w (phospholipid/total composition)) up to 70% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid 15 composition are in a concentration of about 66% (w/w (phospholipids/total composition)).

[0020] In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of above 70% (w/w (phospholipids/total composition)) to about 99% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic 20 phospholipid composition are in a concentration of between about 80% (w/w (phospholipids/total composition)) to about 98% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 85% (w/w (phospholipids/total composition)) to about 95% (w/w (phospholipids/total composition)). In 25 further embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of about 90% (w/w (phospholipids/total composition)).

[0021] In some embodiments, R1 is a monounsaturated fatty acid. In other embodiments, R1 is a polyunsaturated fatty acid. In some embodiments, R2 is a monounsaturated fatty 30 acid. In other embodiments, R2 is a polyunsaturated fatty acid. In other embodiments, the polyunsaturated fatty acid is an omega 3 fatty acid. In still other embodiments, both R1 and R2 are each independently selected from an omega 3 fatty acid. When at least one of R1 and R2 is an omega 3 fatty acid, the concentrated therapeutic phospholipid composition comprising compounds of Formula I is known as an OM3:PL.

5 **[0022]** In other embodiments, R1 is docosahexaenoic acid (DHA). In other embodiments, R2 is a monounsaturated fatty acid and R1 is DHA. In other embodiments, R2 is a polyunsaturated fatty acid and R1 is DHA. In other embodiments, R2 is an omega 3 fatty acid and R1 is DHA. In still further embodiments, R2 is EPA and R1 is DHA. In still further embodiments, R2 is DHA and R1 is DHA.

10 **[0023]** In other embodiments, R1 is eicosapentaenoic acid (EPA). In other embodiments, R2 is a monounsaturated fatty acid and R1 is EPA. In other embodiments, R2 is a polyunsaturated fatty acid and R1 is EPA. In other embodiments, R2 is an omega 3 fatty acid and R1 is EPA. In still further embodiments, R2 is DHA and R1 is EPA. In still further embodiments, R2 is EPA and R1 is EPA.

15 **[0024]** In another embodiment, R2 is DHA. In other embodiments, R1 is a monounsaturated fatty acid and R2 is DHA. In other embodiments, R1 is a polyunsaturated fatty acid and R2 is DHA. In other embodiments, R1 is an omega 3 fatty acid and R2 is DHA.

20 **[0025]** In other embodiments, R2 is EPA. In other embodiments, R1 is a monounsaturated fatty acid and R2 is EPA. In other embodiments, R1 is a polyunsaturated fatty acid and R2 is EPA. In other embodiments, R1 is an omega 3 fatty acid and R2 is EPA.

25 **[0026]** In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have predominantly DHA at the R2 position of Formula I. In other embodiments, there is more DHA in the compounds of Formula I in the concentrated therapeutic phospholipid composition than EPA. In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 60% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 70% DHA. In other
30 embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 80% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 90% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 95% DHA.

5 **[0027]** In some embodiments, there are free fatty acids in the concentrated therapeutic phospholipid composition, in addition to the fatty acids esterified to the phosphate. In other embodiments, there are essentially no free fatty acids (also expressed as 0% free fatty acids (or FFA)) in the concentrated therapeutic phospholipid composition.

10 **[0028]** In other embodiments, the ratio of the total amount of DHA to EPA in the concentrated therapeutic phospholipid composition is between about 1:1 and 1:0.1. In some embodiments, the ratio is between about 1:0.7 and about 1:0.3. In other embodiments, the ratio is about 1:0.5.


15 **[0029]** In some embodiments, the ratio of the total amount of EPA to DHA in the compounds of Formula I in the concentrated therapeutic phospholipid composition is between about 1:1 and 1:0.1. In some embodiments, the ratio is between about 1:0.7 and about 1:0.3. In other embodiments, the ratio is about 1:0.5.

20 **[0030]** In some embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is between about 20% and about 50%. In other embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is between about 30% and about 45%. In other embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is about 40%.

25 **[0031]** In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is between about 5% and 20%. In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is between about 10% and 15%. In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is about 14%.


30 **[0032]** In some embodiments, the total amount of EPA in the concentrated therapeutic phospholipid composition is between about 10% and 30%. In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is between about 15% and 25%. In some embodiments, the total amount of EPA in the concentrated therapeutic phospholipid composition is about 22%.

- 5 [0033] In some embodiments, X is $-\text{CH}_2\text{CH}_2\text{NH}_3$. In other embodiments, X is $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$. In some embodiments, X is



- 10 [0034] In some embodiments, the concentrated therapeutic phospholipid composition comprises predominantly phospholipids containing $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ (also known as a phosphoydyl-N-trimethylethanolamine).

- [0035] In other embodiments, the concentrated therapeutic phospholipid composition further comprises an antioxidant. In some embodiments, the antioxidant is a carotenoid. In other embodiments, the carotenoid is pro-vitamin A. In other embodiments, the antioxidant is a flavonoid. In other embodiments, the flavonoid is selected from naringin, naringenin, hesperetin/kaempferol, rutin, luteolin, neohesperidin, quecertin. In other embodiments, the flavonoid is



- 20 [0036] In some embodiments, the concentration of the flavonoid is between about 1 mg/kg (w/w of composition) and about 20 mg/kg (w/w of composition). In other embodiments, the concentration of the flavonoid is greater than about 10 mg/kg (w/w of composition).

5 **[0037]** In further embodiments, the concentrated therapeutic phospholipid composition has a concentration of astaxanthin greater than 2000 mg/kg (w/w of composition). In still other embodiments, the concentration of astaxanthin is between about 2,000 mg/kg (w/w of composition) and about 5,500 mg/kg (w/w of composition).

10 **[0038]** In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 22% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 15% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 10% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 5% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of about 1% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below 1% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of 0% (w/w of composition).

25 **[0039]** In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 1% (w/w) and about 20% (w/w). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 5% (w/w) and about 17% (w/w). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 10% (w/w) and about 15% (w/w).

30 **[0040]** In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration between about 0% (w/w) and about 30% (w/w). In other embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration between about 5% and about 20%. In still further embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration between about 10% and about 15%.

5 **[0041]** In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 15%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 10%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 5%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration about 1%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below 1%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration of about 0%.

15 **[0042]** In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 50% compounds of Formula I (w/w), wherein at least 15% of the fatty acid content is EPA, at least 9 % of the fatty acid content is DHA, and at least 0.1% astaxanthin (w/w). In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 66% compounds of Formula I (w/w), wherein at least 20% of the fatty acid content is EPA, at least 12 % of the fatty acid content is DHA, and at least 0.4% astaxanthin (w/w). In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 90% compounds of Formula I (w/w) , at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA, and 0.4% astaxanthin (w/w).

25 **[0043]** In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 50% compounds of Formula I (w/w composition), wherein at least 15% of the fatty acid content is EPA, at least 9 % of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 66% compounds of Formula I (w/w), wherein at least 20% of the fatty acid content is EPA, at least 12 % of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises above 70% compounds of Formula I(w/w), wherein at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises above 90% compounds of Formula I(w/w), wherein at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA.

5 [0044] In one aspect, a concentrated therapeutic phospholipid composition is described comprising compounds of Formula at a concentration of about 66% (w/w (phospholipids/total composition) a free fatty acid (FFA) concentration of less than 6% (w/w FFA/total composition) and a triglyceride concentration of about 0%, the composition being useful for treating and preventing cardiometabolic disorders / metabolic syndrome. In some
10 embodiments, 1 g of the concentrated therapeutic phospholipid composition comprises about 387 mg of total OM3 fatty acids wherein EPA is at about 215 mg and DHA is at about 136 mg) and astaxanthine at about 5 mg.

[0045] In one aspect, a concentrated therapeutic phospholipid composition is described comprising compounds of Formula at a concentration of above 70% (w/w
15 (phospholipids/total composition), a free fatty acid (FFA) concentration of about 0% and a triglyceride concentration of about 0%, the composition being useful for treating and preventing neurodegenerative and neurodevelopmental disorders and diseases.

[0046] In one aspect, the invention is based in part on the unexpected and surprising discovery that concentrated therapeutic phospholipid compositions are useful in modulating
20 plasma triglyceride levels as well as plasma HDL C levels, while not elevating LDL C levels. This unexpected and surprising discovery is useful in the treatment or prevention of disorders associated with increased triglyceride levels, increased LDL-C levels and decreased HDL-C levels. Such diseases and disorders include but are not limited to cardiometabolic disorders / metabolic syndrome (MetS), neurodevelopmental and neurodegenerative diseases/disorders,
25 and inflammation disorders.

[0047] In another aspect, a method of treating or preventing a cardiometabolic disorder / metabolic syndrome is described, the method comprising administering to a subject in need thereof a concentrated therapeutic phospholipid composition. In some embodiments, the cardiometabolic disorder is selected from atherosclerosis, arteriosclerosis, coronary heart
30 (carotid artery) disease (CHD or CAD), acute coronary syndrome (or ACS), valvular heart disease, aortic and mitral valve disorders, arrhythmia / atrial fibrillation, cardiomyopathy and heart failure, angina pectoris, acute myocardial infarction (or AMI), hypertension, orthostatic hypotension, shock, embolism (pulmonary and venous), endocarditis, diseases of arteries, the aorta and its branches, disorders of the peripheral vascular system (peripheral arterial disease or PAD), Kawasaki disease, congenital heart disease (cardiovascular defects) and stroke
35 (cerebrovascular disease), dyslipidemia, hypertriglyceridemia, hypertension, heart failure,

- 5 cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency, phospholipid
- 10 deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel and diabetic autonomic neuropathy.
- 15 In some instances, the methods described above for treating or preventing a cardiometabolic disorder / metabolic syndrome may utilize concentrated therapeutic phospholipid compositions having a concentration of 66% (w/w (phospholipids/composition)).

- [0048] In another aspect, methods of treating, preventing, or improving cognition and /or a cognitive disease, disorder or impairment (memory, concentration, learning (deficit)), or of
- 20 treating or preventing neurodegenerative disorders are described, the method comprising administering to a subject in need thereof a concentrated therapeutic phospholipid composition. In some embodiments, the cognitive disease, disorder or impairment is selected from Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), autism/autism spectrum disorder (ASD), (dyslexia, age-associated memory impairment and
- 25 learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-Alzheimer's disease, Alzheimer's disease, epilepsy, Pick's disease, Huntington's disease, Parkinson disease, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia, dentatorubropallidolusian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia, amyotrophic lateral sclerosis, familial spastic
- 30 paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well being, neurodevelopmental,
- 35 neurodegenerative disorders, hormonal disorders, neurological imbalance or any combinations thereof. In a specific embodiment, the cognitive disorder is memory impairment. In some instances, the methods described above for treating, preventing, or

- 5 improving cognition and /or a cognitive disease, disorder or impairment (memory, concentration, learning (deficit)), or of treating or preventing neurodegenerative disorders may utilize concentrated therapeutic phospholipid compositions having a concentration of greater than 70% (w/w (phospholipids/composition)).

[0049] In another aspect, a method for inhibiting, preventing, or treating inflammation or
10 an inflammatory disease is described, the method comprising administering to a subject in need thereof, a concentrated therapeutic phospholipid composition. In some embodiments, the inflammation or inflammatory disease is selected from organ transplant rejection; reoxygenation injury resulting from organ transplantation (see Grupp *et al.*, J. Mol. Cell
Cardiol. 31: 297-303 (1999)) including, but not limited to, transplantation of the following
15 organs: heart, lung, liver and kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases (IBD) such as ileitis, ulcerative colitis (UC), Barrett's syndrome, and Crohn's disease (CD); inflammatory lung diseases such as asthma, acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease
20 (COPD); inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis; inflammatory diseases of the skin including sclerodermatitis, psoriasis and eczema; inflammatory diseases
25 of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, Epilepsy, amyotrophic lateral sclerosis and viral or autoimmune encephalitis, preeclampsia; chronic liver failure, brain and spinal cord trauma, and cancer. The inflammatory disease can
30 also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to proinflammatory cytokines, *e.g.*, shock associated with proinflammatory cytokines. Such shock can be induced, *e.g.*, by a chemotherapeutic agent that is administered as a treatment for cancer. Other disorders include depression, obesity, allergic diseases, acute
35 cardiovascular events, muscle wasting diseases, and cancer cachexia. Also inflammation that results from surgery and trauma can be treated with the concentrated therapeutic phospholipid compositions.

5 **[0050]** The details of the invention are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular
10 forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.

DESCRIPTION OF THE FIGURES

- 15 **[0051]** FIG. 1A depicts a flow chart for the process for making the concentrated therapeutic phospholipid compositions.
- [0052]** FIG. 1B depicts a flow chart for the process for making the concentrated therapeutic phospholipid compositions.
- [0053]** FIG. 1C depicts shows the schematic of the supercritical CO₂ extraction
20 apparatus.
- [0054]** FIG. 2 depicts circulating plasma triglyceride concentration of C57BL/6 mice treated with Composition 3.
- [0055]** FIG. 3 depicts circulating plasma HDL-Cholesterol concentration of C57BL/6 mice treated with Composition 3.
- 25 **[0056]** FIG. 4 depicts circulating plasma percentage of HDL-Cholesterol in C57BL/6 mice treated with Composition 3.
- [0057]** FIG. 5 depicts circulating plasma LDL-Cholesterol concentration of C57BL/6 mice treated with Composition 3.
- [0058]** FIG. 6 depicts circulating plasma percentage of LDL-Cholesterol in C57BL/6
30 mice treated with Composition 3.
- [0059]** FIG. 7 depicts circulating plasma NEFA concentration of C57BL/6 mice treated with Composition 3.
- [0060]** FIG. 8 depicts circulating plasma Glucose concentration of C57BL/6 mice treated with Composition 3.
- 35 **[0061]** FIG. 9 depicts circulating plasma Phospholipid concentration of C57BL/6 mice treated with Composition 3.

- 5 **[0062]** FIG. 10 depicts circulating plasma ALT concentration of C57BL/6 mice treated with Composition 3.
- [0063]** FIG. 11 depicts liver Total Cholesterol concentration of C57BL/6 mice treated with Composition 3.
- [0064]** FIG. 12 depicts liver Triglyceride concentration of C57BL/6 mice treated with
- 10 Composition 3.
- [0065]** FIG. 13 depicts circulating plasma triglyceride concentration of LDLr KO mice treated with Composition 3.
- [0066]** FIG. 14 depicts circulating plasma HDL-Cholesterol concentration of LDLr KO mice treated with Composition 3.
- 15 **[0067]** FIG. 15 depicts circulating plasma percentage of HDL-Cholesterol in LDLr KO mice treated with Composition 3.
- [0068]** FIG. 16 depicts liver Total Cholesterol concentration of LDLr KO mice treated with Composition 3.
- [0069]** FIG. 17 depicts liver Triglyceride concentration of LDLr KO mice treated with
- 20 Composition 3.
- [0070]** FIG. 18 depicts circulating plasma Triglyceride concentration of ApoA-1 CET Tg mice treated with Composition 3.
- [0071]** FIG. 19 depicts circulating plasma total cholesterol concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- 25 **[0072]** FIG. 20 depicts circulating plasma total cholesterol concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- [0073]** FIG. 21 depicts circulating plasma HDL/LDL concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- [0074]** FIG. 22 depicts circulating plasma total cholesterol/HDL concentration of adult
- 30 male SD, ZDF, SHR and JCR:LA rats.
- [0075]** FIG. 23 depicts prothrombin time of adult male SD, ZDF, SHR and JCR:LA rats.
- [0076]** FIG. 24 depicts OGTT area under the curve data in ZDF male rats treated with Composition 3 for 28 days.
- [0077]** FIG. 25 depicts OGTT area under the curve data in ZDF male rats treated with
- 35 Composition 3 for 28 days.
- [0078]** FIG. 26 depicts OGTT area under the curve data in SD male rats treated with Composition 3 for 28 days.

- 5 [0079] FIG. 27 depicts OGTT area under the curve data in ZDF male rats treated with Composition 3 for 28 days.
- [0080] FIG. 28 depicts the effects of Composition 3 on plasma total cholesterol in male ZDF rats compared to age-matched controls.
- [0081] FIG. 29 depicts the effects of Composition 3 on plasma HDL-cholesterol in male ZDF rats compared to age-matched controls.
- 10 [0082] FIG. 30 depicts the effects of Composition 3 on plasma triglycerides in male ZDF rats compared to age-matched controls.
- [0083] FIG. 31 depicts the effects of Composition 3 on glucose intolerance in male ZDF rats.
- 15 [0084] FIG. 32 depicts the effects of Composition 3 on glucose intolerance in male ZDF rats.
- [0085] FIG. 33 depicts the effects of Composition 3 on glucose intolerance in male SD rats.
- [0086] FIG. 34 depicts the effects of Composition 3 on glucose intolerance in male SD rats.
- 20 [0087] FIG. 35 depicts the comparative effects of Composition 3 and Lovaza^(R) on the Omega-3 Index.

DETAILED DESCRIPTION OF THE INVENTION

- [0088] It has been unexpectedly discovered that concentrated therapeutic phospholipid compositions demonstrate surprising effects in the treatment of metabolic disorders, cardiovascular disease, neurodevelopmental disorders and neurodegenerative diseases, and inflammation disorders.
- 25

DEFINITIONS

- [0089] The following definitions are used in connection with the concentrated therapeutic phospholipid compositions:
- 30 [0090] The term “concentrated therapeutic phospholipid composition” and “concentrated therapeutic phospholipid compositions” as used herein refer to the concentrated therapeutic phospholipid compositions comprising compounds of Formula I.

5 [0091] The articles “a” and “an” are used in this disclosure to refer to one or more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0092] The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.

10 [0093] The term “about” when used in this disclosure along with a recited value means the value recited and includes the range of + or – 5 % of the value. For example, the phrase about 80% means 80% and + or – 5% of 80, *i.e.* 76% to 84%. The recited value “about 0%” as used herein means that the detectable amount is less than one part per thousand.

[0094] The term “fatty acid” or “fatty acid residue” as used herein means a carboxylic acid with a long unbranched aliphatic chain, which is either saturated or unsaturated. Saturated fatty acids have the general formula $C_nH_{2n+1}COOH$. Examples of saturated fatty acids include but are not limited to: Propanoic acid, Butanoic acid, Pentanoic acid, Hexanoic acid, Heptanoic acid, Octanoic acid, Nonanoic acid, Decanoic acid, Undecanoic acid, Dodecanoic acid, Tridecanoic acid, Tetradecanoic acid, Pentadecanoic acid, Hexadecanoic acid, Heptadecanoic acid, Octadecanoic acid, Nonadecanoic acid, Eicosanoic acid, Heneicosanoic acid, Docosanoic acid, Tricosanoic acid, Tetracosanoic acid, Pentacosanoic acid, Hexacosanoic acid, Heptacosanoic acid, Octacosanoic acid, Nonacosanoic acid, Triacontanoic acid, Henatriacontanoic acid, Dotriacontanoic acid, Tritriacontanoic acid, Tetratriacontanoic acid, Pentatriacontanoic acid, Hexatriacontanoic acid. An unsaturated fat is a fat or fatty acid in which there are one or more double bonds in the fatty acid chain. A fat molecule is monounsaturated if it contains one double bond, and polyunsaturated if it contains more than one double bond. Examples of unsaturated fatty acids include but are not limited to: Myristoleic acid, Palmitoleic acid, Sapienic acid, Oleic acid, Linoleic acid, α -Linolenic acid, Arachidonic acid, Eicosapentaenoic acid (EPA), Erucic acid, Docosahexaenoic acid (DHA), and Docosapentaenoic acid.

25 [0095] A “subject” is a mammal, *e.g.*, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.

[0096] Representative “pharmaceutically acceptable salts” include, *e.g.*, water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2, 2 - disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine,

5 hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, 10 p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

[0097] The term “metabolic disorder” as used herein refers to disorders, diseases and syndromes involving dyslipidemia, and the terms metabolic disorder, metabolic disease, and metabolic syndrome are used interchangeably herein.

15 [0098] An “effective amount” when used to describe an amount of a concentrated therapeutic phospholipid composition useful for treating or preventing a disease or disorder, is an amount that is efficacious with respect to the disease or disorder connected with that particular effective amount.

[0099] The term “carrier”, as used in this disclosure, encompasses carriers, excipients, 20 and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.

[0100] The term “treating”, with regard to a subject, refers to improving at least one 25 symptom of the subject's disorder. Treating can be curing, improving, or at least partially ameliorating the disorder.

[0101] The term “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0102] The term “administer”, “administering”, or “administration” as used in this 30 disclosure refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

35

5 *Methods of Making the Concentrated Therapeutic Phospholipid Compositions*

[0103] The concentrated therapeutic phospholipid compositions can be made or produced by any method known to one of skill in the art. For example, phospholipid containing oils can be isolated from natural sources (see US 2004/0234587, US 2009/0074857, and US 2008/0274203, the disclosures of which are incorporated by reference in their entireties), which can then be further processed. Alternatively, following the process outlined in Figure 1a results in bulk raw material krill oil ready for further processing. These phospholipid containing oils can be further processed using countercurrent supercritical CO₂ extraction (Lucien, F. P., et al., *Australas Biotechnol.* 1993, 3, 143-147) to concentrate the compositions to produce the concentrated therapeutic phospholipid compositions described herein (see Figure 1b). For example, countercurrent supercritical CO₂ extraction at 70 C and 30 MPa and with a CO₂/oil ratio of 72 can be used to remove certain biomolecules such as all triglycerides from the bulk raw material krill oil as well as some of the free fatty acids (Figure 1b). As more of the TGs and FFAs are removed from the bulk raw material krill oil, the concentration of the phospholipids increases. When the TGs have been removed through this process the phospholipid composition is at about 66% concentration (w/w (phospholipids/composition)) and contains less than 5% free fatty acids (w/w). As more of the FFAs are removed using this process, a concentrated therapeutic phospholipid composition results having a phospholipid concentration above 70% up to about 90% (w/w (phospholipids/composition)) having about 1% or less TG and about 0% FFA. Other aquatic and/or marine biomasses may be used as starting materials, such as, for example, squid or blue mussels. Additional components can be added before, during, or after processing. Alternatively, phospholipids can be synthesized; a typical way to synthesize would be, among others, according to the procedure described in US 7,034,168, the disclosure of which is incorporated herein its entirety.

30 *Methods for using the Concentrated Therapeutic Phospholipid Compositions*

[0104] Described herein are methods of reducing circulating plasma concentrations of triglycerides, LDL-cholesterol, total cholesterol and NEFA, the method comprising administering to a subject in need thereof an effective amount of a Composition of the Invention.

35

5 **[0105]** Also provided are methods of increasing plasma concentrations of HDL-cholesterol and hepatic concentrations of triglycerides and total cholesterol, the method comprising administering to a subject in need thereof an effective amount of a concentrated therapeutic phospholipid composition.

10 **[0106]** In another aspect, a method of reducing TG without the risk of increasing LDL is described, the method comprising administering to a subject in need thereof, a concentrated therapeutic phospholipid composition.

15 **[0107]** Also provided are methods for inhibiting, preventing, or treating a metabolic disorder, or symptoms of a metabolic disease, in a subject, the method comprising administering to a subject in need thereof an effective amount of a concentrated therapeutic phospholipid composition. Examples of such disorders include, but are not limited to atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute
20 myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary
25 syndrome (ACS), non-alcoholic fatty liver disease, arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, and diabetic autonomic neuropathy.

30 **[0108]** Also provided are methods for inhibiting, preventing, or treating inflammation or an inflammatory disease in a subject. The inflammation can be associated with an inflammatory disease. Inflammatory diseases can arise where there is an inflammation of the body tissue. These include local inflammatory responses and systemic inflammation. Examples of such diseases include, but are not limited to: organ transplant rejection; reoxygenation injury resulting from organ transplantation (see Grupp *et al.*, J. Mol. Cell
35 Cardiol. 31: 297-303 (1999)) including, but not limited to, transplantation of the following organs: heart, lung, liver and kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome,

5 and Crohn's disease; inflammatory lung diseases such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; inflammatory diseases of the kidney including uremic complications,
10 glomerulonephritis and nephrosis; inflammatory diseases of the skin including sclerodermatitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or
15 autoimmune encephalitis. Metabolic disease such as type II diabetes mellitus; the prevention of type I diabetes; dyslipidemia; diabetic complications, including, but not limited to glaucoma, retinopathy, nephropathy, such as microalbuminuria and progressive diabetic nephropathy, polyneuropathy, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic hyperosmolar coma, mononeuropathies, autonomic
20 neuropathy, joint problems, and a skin or mucous membrane complication, such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabetorum; immune-complex vasculitis, systemic lupus erythematosus; inflammatory diseases of the heart such as cardiomyopathy, ischemic heart disease hypercholesterolemia, and atherosclerosis; as well as various other diseases that can have significant inflammatory components, including
25 preeclampsia; chronic liver failure, brain and spinal cord trauma, and cancer. The inflammatory disease can also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to proinflammatory cytokines, *e.g.*, shock associated with proinflammatory cytokines. Such shock can be induced, *e.g.*, by a chemotherapeutic agent
30 that is administered as a treatment for cancer. Other disorders include depression, obesity, allergic diseases, acute cardiovascular events, muscle wasting diseases, and cancer cachexia. Also inflammation that results from surgery and trauma can be treated with the concentrated therapeutic phospholipid compositions.

35

5 [0109] Also provided are methods for inhibiting, preventing, or treating hypertriglyceridemia in subject. In some embodiments, the hypertriglyceridemia is moderate hypertriglyceridemia. In some embodiments, the subject is diagnosed with moderate hypertriglyceridemia. Moderate hypertriglyceridemia is defined as a subject having a TG level of > 3.9 mmol/L (>350 mg/dL).

10

[0110] Also provided are methods for reducing fasting plasma levels of Low-density Lipoprotein Cholesterol (LDL-C) in a subject. In some embodiments of reducing fasting plasma levels of Low-density Lipoprotein Cholesterol (LDL-C), the subject is diagnosed with moderate hypertriglyceridemia.

15

[0111] Also provided are methods for increasing fasting plasma levels of High-density Lipoprotein Cholesterol (HDL-C) in a subject. In some embodiments of increasing fasting plasma levels of High-density Lipoprotein Cholesterol (HDL-C), the subject is diagnosed with moderate hypertriglyceridemia.

20

[0112] Also provided are methods for increasing the Omega-3 index (OM3I) in a subject. The Omega-3 Index is defined as the percentage of EPA+DHA in red blood cells (RBC) which can be represented by the formula: $OM3I = (EPA + DHA) / \text{Total fatty acids in RBC}$. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death and can be viewed as a marker of increased risk (an actual risk factor) for death from coronary heart disease (Harris, 2010). In other embodiments, the method provided elevates the omega-3 index (OM3I) and reduces oral glucose intolerance (OGTT). In some embodiments of increasing omega-3 index, the subject is diagnosed with moderate hypertriglyceridemia.

25

[0113] Also provided are methods for reducing high sensitivity C-reactive protein (hs-CRP) in a subject. In some embodiments of reducing high sensitivity C-reactive protein (hs-CRP), the subject is diagnosed with moderate hypertriglyceridemia.

30

35

5 [0114] Also provided are methods for inhibiting, preventing, or treating cardiovascular disease in a subject. Cardiovascular diseases include atherosclerosis, arteriosclerosis, coronary artery disease, heart valve disease, arrhythmia, heart failure, hypertension, orthostatic hypotension, shock, endocarditis, diseases of the aorta and its branches, disorders of the peripheral vascular system, and congenital heart disease.

10

[0115] Also provided are methods for inhibiting, preventing, or treating metabolic syndrome in a subject. Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. It affects one in five people, and prevalence increases with age. Some studies estimate the prevalence in the USA
15 to be up to 25% of the population. Metabolic syndrome is also known as metabolic syndrome X, syndrome X, insulin resistance syndrome, Reaven's syndrome, and CHAOS (Australia).

[0116] Also provided are methods for inhibiting, preventing, or treating a cognitive
20 disorder, in a subject. The term "cognitive disease or disorder" as used herein should be understood to encompass any cognitive disease or disorder. Non-limiting examples of such a cognitive disease or disorder are Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), dyslexia, age-associated memory impairment and learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-
25 Alzheimer's disease, autism, dystonias and Tourette syndrome, dementia, age related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well being, neurodegenerative disorders,
30 hormonal disorders or any combinations thereof. In a specific embodiment, the cognitive disorder is memory impairment.

[0117] The term "improving a condition in a subject suffering from a cognitive disease or a cognitive disorder" as used herein should be understood to encompass: ameliorating
35 undesired symptoms associated with a disease, disorder, or pathological condition; preventing manifestation of symptoms before they occur; slowing down progression of a disease or disorder; slowing down deterioration of a disease or disorder; slowing down irreversible damage caused in a progressive (or chronic) stage of a disease or disorder; delaying onset of a

5 (progressive) disease or disorder; reducing severity of a disease or disorder; curing a disease or disorder; preventing a disease or disorder from occurring altogether (for example in an individual generally prone to the disease) or a combination of any of the above. For example, in a subject suffering from memory impairment, for example as a result of Alzheimer's Disease, symptoms including deterioration of spatial short-term memory, memory recall
10 and/or memory recognition are improved by use of a lipid concentrated therapeutic phospholipid composition.

[0118] Also provided are methods for inhibiting, preventing, or treating neurodegenerative disorder in a subject. Neurodegenerative disorder is defined as a chronic
15 progressive neuropathy characterized by selective and generally symmetrical loss of neurons in motor, sensory, or cognitive systems. Non limiting examples of neurodegenerative disorders include but are not limited to Alzheimer's disease, Pick's disease, Lewy body dementia Basal ganglia–Huntington's disease, Parkinson's disease, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia
20 Motor–amyotrophic lateral sclerosis, familial spastic paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia,
25 amyotrophic lateral sclerosis, and familial spastic paraparesis.

[0119] Also provided are methods for reducing the decline of global cognitive function in a subject. In some embodiments, the reduction in decline of global cognitive function can be measured by the Neuropsychological Test Battery (NTB). In some embodiments, the subject
30 is diagnosed with early stage Alzheimer's disease.

[0120] Also provided are methods for reducing worsening of neuropsychiatric symptoms in a subject. In some embodiments, the reduction is measured by the Neuropsychiatric Inventory questionnaire (NPI). In some embodiments, the subject is diagnosed with early
35 stage Alzheimer's disease.

5 [0121] Also provided are methods for maintaining self-care and activities of daily living function in a subject suffering from Alzheimer's disease. In some embodiments, the subject is diagnosed with early stage Alzheimer's disease. In some embodiments, the maintaining self-care and activities of daily living function is measured by the Disability Assessment in Dementia caregiver-based interview (DAD).

10 [0122] Additional health disorders or conditions which may be treated or improved by the concentrated therapeutic phospholipid compositions include, but are not limited to, high blood cholesterol levels, high triglycerides levels, high blood fibrinogen levels, low HDL/LDL ratio, menopausal or post-menopausal conditions, hormone related disorders,
15 vision disorders, immune disorders, liver diseases, chronic hepatitis, steatosis, lipid peroxidation, dysrhythmia of cell regeneration, destabilization of cell membranes, high blood pressure, cancer, hypertension, aging, kidney disease, skin diseases, edema, gastrointestinal diseases, peripheral vascular system diseases, allergies, airways diseases, and psychiatric diseases.

20 *Combination Therapies*

[0123] In some embodiments, the subject is administered an effective amount of a concentrated therapeutic phospholipid composition. In other embodiments, the treatment comprises a combination of a concentrated therapeutic phospholipid composition and
25 treatment agents such as anti-dyslipidemic agents. Anti-dyslipidemic agents include but are not limited to atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

[0124] In other embodiments, the treatment comprises a combination of a concentrated
30 therapeutic phospholipid composition and a cholinesterase inhibitor. Cholinesterase inhibitors include but are not limited to metrifonate (irreversible), carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demarcarium, rivastigmine, phenanthrene derivatives, galantamine, piperidines, donepezil, tacrine, edrophonium, huperzine A, ladostigill and ungeremine.

- 5 [0125] In some embodiments, the subject is administered a combination of a concentrated therapeutic phospholipid composition and at least one of vitamins, minerals, cox-inhibitors, sterols, fibrates, antihypertensives, insulin, cholesterol digestion inhibitors, for example, ezetimibe, fatty acids, omega-3 fatty acids, antioxidants, and the methylphenydate class of compounds, such as for example ritalin. In other embodiments, a combination of a
- 10 concentrated therapeutic phospholipid composition and elements depleted during traditional chronic treatments, such as for example during chronic treatment with statins. For example, in some embodiments, a concentrated therapeutic phospholipid composition is described which contains at least one of cox-2, folic acid, vitamin B6, vitamin B12, magnesium or zinc. In other embodiments, combination therapies comprising a concentrated therapeutic
- 15 phospholipid composition and potassium are described. Potassium is usually depleted during treatment with diuretics. Combination therapies reduce risk of side effects, increase benefits, increase solubility, and/or increase bioavailability.

Modes of Administration

- 20 [0126] Administration of the concentrated therapeutic phospholipid compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, parenteral, transdermal, subcutaneous, or topical administration modes.

25 *Pharmaceutical Formulations*

- [0127] Depending on the intended mode of administration, the compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
- 30 Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those skilled in the pharmaceutical arts.
- [0128] Illustrative pharmaceutical compositions are tablets and gelatin capsules
- 35 comprising a concentrated therapeutic phospholipid composition neat, or if required, contains a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, lactose, dextrose, sucrose, mannitol, sorbitol,

5 cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, *e.g.*, silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, *e.g.*, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such
10 as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, *e.g.*, starches, agar, methyl cellulose, bentonite, xanthan gum, algiic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909,
15 labrafac, labrafil, peceol, transcutoil, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.

[0129] Liquid, particularly injectable, compositions can, for example, be prepared by
20 dissolution, dispersion, *etc.* For example, the concentrated therapeutic phospholipid composition is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the concentrated therapeutic phospholipid
25 composition.

[0130] Other illustrative topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of the concentrated therapeutic phospholipid composition ranges from about 0.1 % to about 15 %, w/w or w/v.

30 *Dosing*

[0131] The dosage regimen utilizing the concentrated therapeutic phospholipid compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated;
35 the route of administration; the renal or hepatic function of the subject; and the particular concentrated therapeutic phospholipid composition employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

5 [0132] Effective dosage amounts of the present invention, when used for the indicated effects, range from about 20 mg to about 10000 mg of the concentrated therapeutic phospholipid composition per day. Dosages for *in vivo* or *in vitro* use can contain about 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, 5000, 7500 or 10000 mg of the concentrated therapeutic phospholipid composition. Effective blood plasma levels after
10 administration of the concentrated therapeutic phospholipid composition to a subject can range from about 0.002 mg to about 100 mg per kg of body weight per day. Appropriate dosages of the concentrated therapeutic phospholipid composition can be determined as set forth in L.S. Goodman, *et al.*, *The Pharmacological Basis of Therapeutics*, 201-26 (5th ed.1975).

15

[0133] The concentrated therapeutic phospholipid compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage
20 regimen. In some embodiments, of combination therapy, the concentrated therapeutic phospholipid composition and the therapeutic agent can be administered simultaneously. In other embodiments, the concentrated therapeutic phospholipid composition and the therapeutic agent can be administered sequentially. In still other embodiments of combination therapy, the concentrated therapeutic phospholipid composition can be
25 administered daily and the therapeutic agent can be administered less than daily. In still other embodiments of combination therapy, the concentrated therapeutic phospholipid composition can be administered daily and the therapeutic agent can be administered more than once daily.

EXAMPLES

30 [0134] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications,
35 and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.

5

Concentrated Therapeutic Phospholipid Compositions

[0135] The following non-limiting examples of therapeutic compositions serve to illustrate further embodiments of the concentrated therapeutic phospholipid composition. It is to be understood that any embodiments listed in the Examples section are embodiments of the concentrated therapeutic phospholipid composition and, as such, are suitable for use in the methods and compositions described above.

[0136] The following methods can be used to make the concentrated therapeutic phospholipid compositions (Figure 1A and 1B)

Step 1:

[0137] Frozen krill is mechanically crushed and incubated with a solvent in a ratio of 9:1 acetone water for 60-90 minutes at 8°C to extract different proportions of the lipids (PL, TG and FFA) from the krill biomass. Lipids are subsequently separated from proteins and krill material by filtration under pressure (50-60 kpa). The solid phase is discarded. The soluble extract is evaporated by a continuous distillation column under vacuum to remove the solvent (acetone). The major part of the aqueous (water) fraction is separated from the lipid fraction by decantation and the remaining water removed by evaporation under vacuum and gentle heating. Those fractions are dosed, analyzed, and blended to constitute an intermediary krill oil product which is re-analyzed to achieve desired specifications $\pm 5\%$: EPA (15g/100g), DHA (9g/100g), total phospholipids (42g/100g) and astaxanthin's forms (125mg/100g).

Step 2:

[0138] 100.5g of received krill oil from step 1 was charged to a 300ml extraction vessel (ID = 0.68"). The extractor was sealed, pre-heated CO₂ at 55°C was introduced from the bottom, and the pressure in the extractor was maintained at 5,000 psi using a diaphragm CO₂ pump. The flow of CO₂ was continued in the upflow direction through the extractor and was expanded to atmospheric pressure through a pressure-reduction-valve (PRV) so that the dissolved material in the CO₂ precipitated and collected in the flask. The flow rate and volume of CO₂ exiting the flask was measured with a flowmeter and dry test meter (DTM). A total of 7200g of CO₂ was passed through the extractor (solvent to feed ratio, S/F = 72) and 34.1% of the charge was removed by the CO₂. The flow of about 25 Standard Liters/min of CO₂ was maintained during the course of the test and the total time of extraction was

- 5 about 160min. The extractor was isolated and the CO₂ was vented to atmosphere. The extractor was opened and the un-extracted material (raffinate-product) was removed from the vessel.

Step 3:

- [0139] SC CO₂ Extraction to produce 90+% OM3:PLs. 9.44g of oil was mixed with
10 inert packing and charged to the extractor. The procedure carried out similar to that described in step 2 except more aggressive extraction conditions were used with the pressure and temperature in the extractor maintained at 10,000 psi and 70°C. A total S/F ratio of 200 was used f; therefore, about 1900g of CO₂ was flowed through the extractor. A flow rate of CO₂ of about 10 Standard Liters/min was maintained; therefore, the total run time for this test was
15 105min. A total of 56.3% of the charge was extracted from this oil during the course of the run. The extractor was isolated, the CO₂ vented to atmosphere, the vessel opened, and the resulting raffinate-product scraped off the inert packing. This un-extracted material analyzed to be 91% OM3:PLs.

Composition 1

47 % OM3:PL			
*Total lipids as FA _{TG}	g/100g oil	61.3	(100)
*Omega-3	g/100g oil	14.1	(22,5)
*EPA	g/100g oil	7.4	(11,6)
*DHA	g/100g oil	3.8	(6,1)
*DPA	g/100g oil	0.2	(0,3)
*Omega-6	g/100g oil	10.8	(18,3)
*Linoleic acid	g/100g oil	10.6	(18,0)
*Omega-9	g/100g oil	6.6	(11,6)
*Oleic acid	g/100g oil	6.1	(10,8)
*Sat. FA _{TG}	g/100g oil	21.4	(36,1)
*Monounsatur. FA _{TG}	g/100g oil	13.9	(23,1)
*Polyunsatur. _{TG}	g/100g oil	26.0	(40,7)
*EPA as FA _{TG}	g/100g oil	7.7	
*DHA as FA _{TG}	g/100g oil	3.9	
Water	%	0.8	
Color	-	Red orange	
Odor	-	Slightly rancid	
Total carotenoids	mg/100g oil	36.0	
Astaxanthine	mg/100g oil	65.3	
Astaxanthine	% diester	83.1	
	% monoester	16.9	
	% free	0.0	
Peroxide Index	mEq peroxide/kg	1.0	
p-Anisidine Index	-	2.0	
Iodine Index	gI ₂ /100g oil	101.1	
Saponification Index	mg KOH/g oil	214.1	
Indice acide	mg KOH/g oil	17.2	
Total fat	%		
Free fatty acid	% as oleic acid	5.2	
Triglycerides	%	36.5	
Viscosity	cP	1323.0	
ash	%	5.0	
Vitamin A	UI/g Oil	40.4	
Vitamin E	UI/g Oil	0.1	
Total phospholipids	g/100g oil	47.2	
Phospholipid profile	TLC	-	
	% LPC	3.7	
	% PC	53.6	
	% PS	24.7	
	% PE	16.4	
	% PA	1.7	
Molecular mass PL	g/mol	773.8	

Composition 2

53% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	69.80
Total Omega-3	g / 100 g oil	31.30
C 20:5 (n=3) EPA	g / 100 g oil	13.90
C 22:6 (n=3) DHA	g / 100 g oil	10.10
C 22:5 (n=3) DPA	g / 100 g oil	0.40
Total Omega-6	g / 100 g oil	1.60
linoleic acid – LA	g / 100 g oil	1.30
Total Omega-9	g / 100 g oil	6.10
oleic acid – OA	g / 100 g oil	5.70
Saturated FA	g / 100 g oil	21.10
Monounsaturated FA	g / 100 g oil	14.50
Polyunsaturated FA	g / 100 g oil	34.20
EPA as FA	g / 100 g oil	14.40
DHA as FA	g / 100 g oil	10.50
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	52.30
lysophosphatidyl choline - LPC	%	10.80
sphingomyeline - SM	%	0.10
phosphatidyl choline - PC	%	79.70
phosphatidyl serine - PS	%	
phosphatidyl inositol - PI	%	
phosphatidyl ethanolamine - PE	%	9.40
PA	%	0.00
CAROTENOIDS		
total	mg / 100 g oil	92.60
total astaxanthin - AST	mg / 100 g oil	161.60
AST diester		62.00
AST monoester		35.00
AST free		3.00

Composition 3

66% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	74.2
Total Omega-3	g / 100 g oil	39.8
C 20:5 (n=3) EPA	g / 100 g oil	21.7
C 22:6 (n=3) DHA	g / 100 g oil	14.1
C 22:5 (n=3) DPA	g / 100 g oil	0.5
Total Omega-6	g / 100 g oil	1.7
linoleic acid - LA	g / 100 g oil	1.3
Total Omega-9	g / 100 g oil	5.8
oleic acid - OA	g / 100 g oil	5.1
Saturated FA	g / 100 g oil	18.0
Monounsaturated FA	g / 100 g oil	13.2
Polyunsaturated FA	g / 100 g oil	43.1
EPA as FA	g / 100 g oil	22.6
DHA as FA	g / 100 g oil	14.6
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	66.2
lysophosphatidyl choline - LPC	%	10.7
phosphatidyl choline - PC	%	75.3
phosphatidyl ethanolamine - PE	%	11.8
other	%	2.2
CAROTENOIDS		
total	mg / 100 g oil	273.4
total astaxanthin - AST	mg / 100 g oil	466.8
AST diester	%	57.4
AST monoester	%	40.7
AST free	%	1.9

5

Composition 4

80% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	68.35
Total Omega-3	g / 100 g oil	37.90
C 20:5 (n=3) EPA	g / 100 g oil	20.40
C 22:6 (n=3) DHA	g / 100 g oil	12.95
C 22:5 (n=3) DPA	g / 100 g oil	0.48
Total Omega-6	g / 100 g oil	1.45
linoleic acid - LA	g / 100 g oil	1.26
Total Omega-9	g / 100 g oil	4.93
oleic acid - OA	g / 100 g oil	4.35
Saturated FA	g / 100 g oil	16.15
Monounsaturated FA	g / 100 g oil	11.21
Polyunsaturated FA	g / 100 g oil	40.99
EPA as FA	g / 100 g oil	21.30
DHA as FA	g / 100 g oil	13.50
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	80.00
lysophosphatidyl choline - LPC	%	9.20
sphingomyeline - SM	%	0.20
phosphatidyl choline - PC	%	80.60
phosphatidyl serine - PS	%	1.10
phosphatidyl inositol - PI	%	0.10
phosphatidyl ethanolamine - PE	%	7.50
PA	%	1.30
CAROTENOIDS		
total	mg / 100 g oil	180.4
total astaxanthin - AST	mg / 100 g oil	325.5
AST diester	%	68.45
AST monoester	%	29.27
AST free	%	2.28

Composition 5

90% OM3:PL		
*Total lipids as FA _{TG}	g/100g oil	63.9
*Omega-3	g/100g oil	35.1
*EPA	g/100g oil	18.9
*DHA	g/100g oil	12.2
*DPA	g/100g oil	0.5
*Omega-6	g/100g oil	1.3
*Linoleic acid	g/100g oil	1.2
*Omega-9	g/100g oil	4.6
*Oleic acid	g/100g oil	3.9
*Sat. FA _{TG}	g/100g oil	15.8
*Monounsatur. FA _{TG}	g/100g oil	10.2
*Polyunsatur. TG	g/100g oil	37.9
*EPA as FA _{TG}	g/100g oil	19.7
*DHA as FA _{TG}	g/100g oil	12.7
Acetone	Ppm	1.6
Humidity and volatiles	%	1.7
Water	%	1.9
Color	-	Red chili
Odor	-	shellfish
Total carotenoids	mg/100g oil	168.9
Astaxanthine	mg/100g oil	309.3
Astaxanthine	% Diester	73.1
	% Monoester	25.3
	% Libre	1.6
Index p-Anisidine	-	3.1
Index acid	mg KOH/g oil	33.6
Index iodine	gI ₂ /100g oil	
Index saponification	mg KOH/g oil	
Index Peroxide	mEq peroxyde/kg	0.1
Vitamin A	UI/g Oil	15.2
Vitamin E	UI/g Oil	0.3
Fatty acid total	%	97.6
Viscosity	cP	
Total phospholipids	g/100g oil	90.6
Phospholipid profile	TLC	-
	% LPC	13.5
	% SM	0.4
	% PC	76.3
	% Autres PL	1.2
	% PE	7.9
	% PA	0.8
Triglycerides	%	0.0

Composition 6

70% OM3:PL derived from Squid		
*Total lipids as FA _{TG}	g/100g oil	54,5
*Omega-3	g/100g oil	29,1
*EPA	g/100g oil	8,9
*DHA	g/100g oil	18,3
*DPA	g/100g oil	0,2
*Omega-6	g/100g oil	0,7
*Linoleic acid	g/100g oil	0,3
*Omega-9	g/100g oil	4,2
*Oleic acid	g/100g oil	2,0
*Sat. FA _{TG}	g/100g oil	16,9
*Monounsatur. FA _{TG}	g/100g oil	6,8
*Polyunsatur. FA _{TG}	g/100g oil	30,9
*EPA as FA _{TG}	g/100g oil	9,3
*DHA as FA _{TG}	g/100g oil	19,1
Humidity (calmar)	%	
Indice acide	mg KOH/g oil	55,7
Vitamin A	UI/g Oil	
Vitamin E	UI/g Oil	
Fatty acid total	%	2,7
Total carotenoids	mg/100g oil	8,3
Astaxanthine	mg/100g oil	13,2
Astaxanthine	% diester	42,5
	% monoester	35,6
	% libre	21,9
Total phospholipids	g/100g oil	70,8*
Phospholipid profile	TLC	-
	% LPC	12,4
	% SM	7,8
	% PC	55,8
	% other	2,0
	% PE	22,0
	% PA	6,4
Triglycerides	%	25,0
Free fatty acid	% as oleic acid	3,2
Index p-Anisidine	-	4,3
Index Peroxide	mEq peroxyde/kg	0,6
**PM Phospholipids (g/mol)		847,14
<i>Profile of Fatty Acids of the PL</i>		
*Total lipids as FA	g/100g PL	53,9
*Oméga-3	g/100g PL	28,6
*EPA	g/100g PL	9,0
*DHA	g/100g PL	18,3
*DPA	g/100g PL	0,2
*Omega-6	g/100g PL	0,5
*Linoleic acid	g/100g PL	0,2
*Omega-9	g/100g PL	3,6

70% OM3:PL derived from Squid		
*Oleic acid	g/100g PL	1,5
*Sat. FA	g/100g PL	18,3
*Monounsatur. FA	g/100g PL	5,4
*Polyunsatur.FA	g/100g PL	30,2

5

Biological Examples

Example 1

Managing Dyslipidemia in Three Murine Phenotypes

[0140] The aim of this study was to examine the effects of Composition 3 in three age-
 10 /sex-matched murine phenotypes representative of (1) normal healthy non-obese
 normoglycemic control (C57BL6) versus (2) hyperdyslipidemic LDL-receptor gene knockout
 (LDLr -/-) or (3) human apoA-I transgenic mice (Jackson Labs) at 12-w of age: 27.5±0.7 vs
 25.6±0.7 vs 29.2±0.8 gr., respectively; n=7-10/gr. kept according to local and national ethic
 regulations, fed a normal vs a Western-diet regime and water *ad libitum*. Data are presented
 15 as mean±sem and statistics assessed by t- test (unpaired, two-tail) (v5-GraphPad Prism).

[0141] The profile of plasma lipids concentrations (mg/dL) in the above-three untreated
 adult male murine models were as reported in the literature: Total cholesterol (TC): 71.1±3.3
 vs 215.3±10.4 vs 50.3±1.3; triglycerides (TGs): 59.5±4.5 vs 65.1±3.8 vs 53.0±12.9; low-
 density lipoprotein (LDL): 13.3±1.2 vs 101.6±6.7 vs 12.2±1.6; high-density lipoprotein
 20 (HDL): 53.4±3.2 vs 88.8±3.6 vs 24.8±2.6. Six (6) weeks of QD treatment with Composition
 3 (104 vs 208 vs 417 mg/kg (Human equivalent dosing of 500, 1,000 and 2,000 mg/day) in
 C57BL6 led to significant dose-dependent decrease in plasma TGs (up to 60%), reduced LDL
 (up to 28%), elevated HDL (by 17%) but did not affect TC (see Figures 2-12 and Table 1).
 In severely dyslipidemic LDLr-KO mice, Composition 3 led to significant dose-dependent
 25 decrease in plasma TGs, elevated further HDL, caused a slight elevation in TC (only at mid-
 dose) and did not affect LDL (see Figures 13-17 and Table 1). In hApoA-I transgenic mice,
 Composition 3 led to significant decrease in plasma TGs, elevated HDL and did not affect TC
 (see Figure 18 and Table 1). The liver concentrations of TC were the same in all three
 phenotypes but TGs were reduced (19%; p<0.05) in LDLr-KO and elevated (153%; p<0.01)
 30 in hApoA-I, compared to control C57BL6. Treatment with Composition 3 elevated liver TC

- 5 and TGs by up to 12% and 27%, respectively, in C57BL6, by up to 10% and 36% in LDLr-KO and by up to 10% for TC but mixed effects for TGs (-13 to + 12%) in hApoA-I mice, respectively (see Table 2).

Table 1: Effects mediated by 6-weeks treatment with Composition 3 on plasma lipids.

Murine phenotype	Plasma Lipids	Low dose 104 mg/kg (HED: 500mg/day)	Mid-dose 208 mg/kg (HED: 1000mg/day)	High-dose 417 mg/kg (HED: 2000mg/day)
C57BL6	TC	75.9±2.0 up 6.8% (NS)	80.6±3.3 up 13.4% (NS)	78.1±2.7 up 9.8% (NS)
	TGs	32.2±1.6 down 46% (p<0.001)	26.0±2.8 down 56% (p<0.001)	23.8±1.2 down 60% (p<0.001)
	LDL	11.1±1.4 down 15% (NS)	11.2±1.0 down 16% (p<0.05)	9.6±0.7 down 28% (p<0.05)
	HDL	59.4±1.9 up 11% (NS)	63.4±3.5 up 19% (NS)	62.3±2.4 up 17% (p<0.05)
LDLr-KO	TC	219.3±7.4 up 2% (NS)	244.4±7.9 up 14% (p<0.01)	238.5±6.9 up 11% (NS)
	TGs	45.7±2.8 down 30% (p<0.001)	41.7±4.9 down 36% (p<0.01)	36.7±1.6 down 44% (p<0.001)
	LDL	99.2±5.7 down 2% (NS)	116.2±4.4 up 14% (NS)	97.4±6.5 down 4% (NS)
	HDL	90.9±2.5 up 2% (NS)	88.4±4.6 = (NS)	111.2±2.5 up 25% (p<0.001)
hApoA-I transgenic	TC	51.1±1.5 up 2% (NS)	57.2±2.6 up 14% (p<0.05)	50.1±1.4 = (NS)
	TGs	19.3±2.8 down 64% (p<0.05)	43.2±11.7 down 18% (NS)	43.0±8.2 down 19% (NS)
	LDL	10.8±1.0 down 11% (NS)	12.8±2.3 = (NS)	13.9±1.0 up 14% (NS)
	HDL	27.9±2.4 up 13% (NS)	28.6±2.6 up 15% (NS)	21.6±12.8 down 13% (NS)

NS; not significant

Table 2: Plasma lipids at baseline between murine phenotype

Plasma concentrations (mg / dL)	C57BL6 control	LDLr-KO	Variation vs control	hApoA-I transgenic	Variation vs control
total cholesterol (TC)	71.1±3.3	215.3±10.4	up 3-fold p<0.001	50.3±1.3	down 29.3% NS
triglycerides (TGs)	59.5±4.5	65.1±3.8	up 9.4% NS	53.0±12.9	down 10.9% NS
low density lipoprotein (LDL-C)	13.3±1.2	101.6±6.7	up 7.6-fold p<0.001	12.2±1.6	down 8.3% NS
high-density lipoprotein (HDL-C)	53.4±3.2	88.8±3.6	up 166% p<0.001	24.8±2.6	down 54% p<0.001
Liver concentrations (µg / mg)					
total cholesterol (TC)	23.1±0.8	23.6±0.6	= (NS)	25.1±0.5	up 9% (NS)
triglycerides (TGs)	53.0±3.1	42.9±2.1	down 19% p<0.05	81.3±7.4	up 153% p<0.001

NS; not significant

5 [0142] These data indicate that the Composition 3 is an effective modulator of lipid metabolism, mainly at reducing plasma TGs and LDL and elevating HDL. These data indicate that in some embodiments, concentrated therapeutic phospholipid compositions can be effective as a therapy against moderate to severe hypertriglyceridemia. In some
10 anti-dyslipidemic agents can be effective at lowering refractory hypertriglyceridemia.

Example 2

Increase of the circulating plasma concentration of high-density Lipoprotein-Cholesterol (HDL-C) and Reduced Total Cholesterol (TC) / HDL ratio in 12-week old Male Zucker Diabetic Fatty Rats.

15 [0143] The purpose of this study was to examine the effects of the concentrated therapeutic phospholipid compositions in the Zucker Diabetic Fatty rat rodent model for type 2 diabetes with obesity, hyperlipidaemia and insulin resistance (ZDF; Gmi-fa/fa) vs age-/sex-matched normal healthy non-obese normoglycemic lean control SD rat (from Charles River Labs; 12-
20 w, 359±17 vs 439±13 gr.; n=9-12/gr.). Lipid profile (total cholesterol (TC), tryglycerides (TGs), High-Density Lipoprotein-Cholesterol (HDL-C) and TC / HDL ratio were assessed before, 1 and 2 month after QD treatment with Composition 3 (52 versus 260 mg/kg (HED of 500 and 2,500 mg), and kept according to local and national ethic regulations (Formulab high fat 5008 (ZDF) vs normal 5001 (SD) diet regime and water *ad libitum*). Data are presented
25 as Mean±SD (n=2-10) and statistical differences calculated by unpaired two-tailed t test (v5-GraphPad Prism). At 12-w of age, the circulating plasma concentrations of TC, TGs, HDL and TC/HDL ratio were: 4.6±0.9, 11.6±5.9, 2.3±1.1 mmol / L and 2.16±0.62, respectively. Lipids' profile in SD rats were significantly lower at 1.9±0.4, 1.2±0.4, 1.3±0.2 mmol / L and 1.45±0.11, respectively. Daily low and high dose treatment for 60 days did not affect TC and
30 TGs concentrations but increased by 1.7- to 1.8-fold (p<0.01) "good" HDL-cholesterol and decreased the TC / HDL ratio by 26-32% (p<0.01-0.05), respectively.

5

Example 3**Improved Glucose Intolerance in Zucker Diabetic Fatty Rats after Administration of Composition 3**

[0144] The purpose of this study was to investigate the effects of Composition 3 in an overtly dislipidemic, obese, type 2 diabetic rat model. Zucker Diabetic Fatty (ZDF; Gmi-fa/fa) rats were used *versus* age-/sex-matched normal healthy non-obese normoglycemic lean control SD rat (from Charles River Labs; 12-w, 359±17 vs. 439±13 gr.; n=9-12/gr.). Glucose intolerance was assessed conducting an oral glucose tolerance test (OGTT; overnight fasting then single gavage of glucose 2 g/kg rat b.w.) over 180 minutes using glucometer strips (Accu-Chek Aviva, Roche Diagnostics), before and 90 days after treatment with Composition 3 given by QD gavage at 52 versus 260 mg/kg (HED of 500 and 2,500 mg), and kept according to local and national ethic regulations (Formulab high fat 5008 (ZDF) vs normal 5001 (SD) diet regime and water *ad libitum*). Data are presented as Mean±SD and statistical differences calculated by unpaired two-tailed t test (v5-GraphPad Prism).

[0145] At 12-w of age (T_0) fasting circulating plasma concentrations of glucose were 7.8±2.1 vs 5.0 ± 0.6 mmol/L ($p<0.001$) in untreated ZDF vs SD rats. Non-fasting ZDF and SD rats glucose levels were 22.0±4.2 vs 8.6±0.6 mmol / L, respectively. One month later, baseline values increased by 1.9-fold ($p<0.0001$) in fasted ZDF while remaining unchanged in fasted SD. Aging did not affect glucose levels in non-fasted rats. Glucose challenge led to a maximum 2.5-fold ($p<0.0001$) and 1.6-fold ($p<0.0001$) increase in plasma glucose concentrations in untreated fasted ZDF and SD, at 30 and 60 minutes, respectively, returning mostly to initial values after 180 mins. At 16 weeks of age, thirty days (T_{30}) of treatment did not affect either the profile (AUC) or maximum elevation in glucose in SD rats but treatment of ZDF shifted to the right the maximum elevation in plasma glucose (from 30 to 60 minutes), reduced by 61-72% ($p<0.02$) the peak elevation at 30 minutes and reduced by 50-60% ($p<0.0001$) the AUC at either doses of Composition 3, thus back to the AUC observed in untreated glucose challenged SD rats. At 20 weeks of age, 60 days of treatment, either dosing did not further attenuate glucose intolerance. None of the treatment profile affected the plasma and urinary concentrations of glucose (hyperglycemia and glucosuria) in non-fasted ZDF or SD. These data indicate that a short term and low dose chronic administration of Composition 3 significantly improves glycemic control in a model of severe hyperglycemia.

5

Example 4

A randomized, placebo-controlled, double-blind, dose-ranging and multi-centered trial to evaluate the safety and efficacy of concentrated therapeutic phospholipid compositions in the treatment of moderate hypertriglyceridemia.

- 10 Subjects with moderate hypertriglyceridemia treated by physician according to the Canadian Lipid Treatment Guidelines who are treated over 12 weeks with concentrated phospholipid given at doses of 1.0, 2.0 or 4.0g. The primary measure of efficacy will be the percent change in fasting blood circulating serum triglycerides (TGs) between baseline (Week 1) and 12 weeks of treatment. Secondary Outcomes: between baseline and after six weeks and 12
- 15 weeks of treatment: 1) absolute change in fasting plasma TGs; 2) percentage (%) of subjects achieving target TG fasting plasma levels; 3) absolute change in fasting plasma LDL-C, VLDL-C, HDL-C, HDL2-C, HDL3-C, Total Cholesterol, hs-CRP and non-HDL; 4) percentage (%) change in fasting plasma concentrations of LDL-C, VLDL-C, HDL-C, HDL2-C, HDL3-C, TC, hs-CRP and non-HDL; 5) calculated Ratios: a) total cholesterol :
- 20 HDL-C; b) LDL-C : HDL-C; c) TGs : HDL-C; 6) LDL-C-related parameters: a) particle number; b) particle size; c) oxidation; 7) absolute and percent (%) change in fasting plasma concentrations of biomarkers; a) glycated Hemoglobin (HbA1c), b) apolipoprotein A-I (ApoA-I), c) apolipoprotein B-100 (ApoB-100), d) apolipoprotein E (ApoE), e) lipoprotein(a) (Lp(a)), f) adiponectin, g) glucose, h) insulin; 8) calculated ApoB : ApoA-I ratio; 9) fasting
- 25 plasma lipoprotein-associated phospholipase A2 activity (Lp-PLA2); 10) HOMA-IR (homeostasis model assessment of insulin resistance: $[\text{glucose (mmol / L)} \times \text{IRI (microIU / L)} / 22.5]$; 11) plasma concentrations of total EPA and DHA (PK/PD – 25 subjects/group); 12) OM3I (Omega-3 index); 13) Subjects Genetic Polymorphism: a) Lecithin:Cholesterol Acyltransferase (LCAT), b) cholesteryl ester transfer protein (CETP), c) scavenger receptor
- 30 type B-1 (SR-B1), d) ATP Binding Cassette transporter 1 (ABCA1).

5

Example 5

Preclinical non-GLP assessment of efficacy of concentrated therapeutic phospholipid compositions alone or in combination with a statin on modulating blood lipids and the development of atherosclerotic lesions in ApoE null mice fed a Western-type diet.

- 10 Male adult mice (n=135 (15 mice / group) 5-6 weeks of age) weighing about 18-20g each homozygous for the Apoetm1Unc mutation are administered HOW either Vehicle (Water or 0.2%-0.5% Carboxymethylcellulose); composition 3 (1,000 mg/daily HED); composition 3 (2,000 mg/daily HED); or Lipitor (20 mg/daily HED); or composition 3 (1,000 mg/daily HED) + Lipitor (20 mg/daily HED). At 0, 3 months, or 6 months the following assessment
- 15 of values is made relative to: blood Lipids: TC, TGs, LDL, HDL, non-HDL, VLDL (0, 3 and 6 months) (2)Aortic Atherosclerosis (0, 3 and 6 months): a. Thoracic and abdominal aorta will be isolated, trimmed of fat, laid out and pinned on black matrix for photography, and stained with Sudan IV or Oil Red-O. b.Vessel will be imaged for surface involvement using a
- 20 computerized image analysis system (Image ProPlus or NIH Package Software). The data will be computed by group and statistically analyzed. c.Lipid extraction: Following staining and morphometric analysis, aortas will be extracted (Bligh/Dyer). (3) Red blood cells Omega-3 Index (0, 3 and 6 months); (4) Circulating plasma concentration of CRP (0, 3 and 6 months).

25

Example 6**Comparison of Composition 3 with Lovaza® on the Omega 3 Index**

- Male sdult (14 weeks) Sprague-Dawley (SD) rats with an average body weight of >375-425 were fed normal rat chow(diet 5075- normal, standard rat chow). Number of test subjects / group: n=56; n=8 rats / gr. Dosing was QD (single daily dosing/morning) for 12 weeks with
- 30 either (i) Vehicle (ii) Composition 3 52 mpk 500 mg / day HED; (iii) Composition 3 104 mpk 1000 mg / day HED; (iv) Composition 3 416 mpk 4000 mg / day HED; (v) Lovaza® 416 mpk = 4000 mg / day HED. Results are shown in Figure 35.

5

Example 7**Monotherapy study of Concentrated Phospholipids in early stage Alzheimer's Disease**


Subjects will be randomly assigned to receive either concentrated therapeutic phospholipid composition 1 g, fish oil (135 mg EPA: 108 mg DHA) 1 g, or placebo (soy oil) 1 g once daily. The primary outcome measure will be the change in NTB between baseline and 24 weeks of treatment. The Neuropsychological Test Battery (NTB) will be used to monitor and evaluate important cognitive changes. The following 9 components of the NTB are used to determine the outcome for the subject: (1) Wechsler Memory Scale, visual immediate (score range, 0-18), (2) Wechsler Memory Scale verbal immediate (score range, 0-24), (3) Rey Auditory Verbal Learning, Test (RAVLT) immediate (score range, 0-105), (4) Wechsler, Memory Digit Span (score range, 0-24), (5) Controlled Word Association, Test (COWAT), (6) Category Fluency Test (CFT), (7) Wechsler, Memory Scale visual delayed (score range, 0-6), (8) Wechsler, Memory Scale verbal delayed (score range, 0-8), and (9) RAVLT, delayed (score range, 0-30) (Harrison et al. 2007). The RAVLT delayed measure is composed of delayed recall and recognition performance components that are summed to yield a score ranging from 0 to 30, yielding 9 measures of subject performance. Secondary outcome measures will include the change in the NPI and DAD at 24 weeks of treatment. The NPI evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetite and eating abnormalities. The DAD is a caregiver-based interview instrument used to evaluate instrumental and basic activities of daily living in dementia (hygiene, dressing, undressing, continence, eating, meal preparation, telephoning, going on an outing, finance, correspondence, medication, leisure and housework). The NPI also assesses the amount of caregiver distress engendered by each of the neuropsychiatric disorders. Blood is drawn and levels of EPA, DHA and phospholipids is measured.

EQUIVALENTS

[0146] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

CLAIMS

1. A concentrated therapeutic phospholipid composition comprising compounds of the Formula I:



(I)


wherein for each compound of Formula I in the composition:

each R_1 is independently selected from hydrogen or any fatty acid;

each R_2 is independently selected from hydrogen or any fatty acid;

wherein at least one of R_1 and R_2 in each compound of Formula I is a fatty acid; and

each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ or




wherein the total amount of the compounds of Formula I in the composition are at a concentration of between 45% (w/w) to about 99% (w/w).

2. The composition of claim 1, wherein the compounds of Formula I are in a concentration of between about 50% (w/w (phospholipids/total composition)) up to 70% (w/w (phospholipids/total composition)).
3. The composition of claim 2, wherein the compounds of Formula I are in a concentration of between about 60% (w/w (phospholipids/total composition)) to up to 70% (w/w (phospholipids/total composition)).
4. The composition of claim 3, wherein the compounds of Formula I are in a concentration of about 66% (w/w (phospholipids/total composition)).
5. The composition of claim 1, wherein the compounds of Formula I are in a concentration of above 70% (w/w (phospholipids/total composition)) to about 99% (w/w (phospholipids/total composition)).
6. The composition of claim 5, wherein the compounds of Formula I are in a concentration of between about 80% (w/w (phospholipids/total composition)) to about 95% (w/w (phospholipids/total composition)).
7. The composition of claim 6, wherein the compounds of Formula I are in a concentration of about 90% (w/w (phospholipids/total composition)).
8. The composition of claim 1, wherein both R1 and R2 are each independently an omega 3 fatty acid.
9. The composition of claim 1, wherein R1 is DHA.
10. The composition of claim 1, wherein R2 is DHA.
11. The composition of claim 1, wherein R1 is EPA.
12. The composition of claim 1, wherein R2 is EPA.
13. The composition of claim 1, wherein R2 is DHA and R1 is EPA.
14. The composition of claim 1, wherein R2 is EPA and R1 is EPA.

15. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has about the same amount of EPA and DHA.
16. The concentrated therapeutic phospholipid composition of claim 1, wherein the the composition has predominantly DHA at the R2 position of Formula I.
17. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has more DHA than EPA.
18. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has greater than 60% DHA of the total fatty acids.
19. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has greater than 70% DHA of the total fatty acids.
20. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has greater than 80% DHA of the total fatty acids.
21. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has greater than 90% DHA of the total fatty acids.
22. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition has greater than 95% DHA of the total fatty acids.
23. The concentrated therapeutic phospholipid composition of claim 1, wherein the free fatty acid concentration is between about 0% (w/w) and about 20% (w/w).
24. The concentrated therapeutic phospholipid composition of claim 23, wherein the free fatty acid concentration of between about 5% (w/w) and about 17% (w/w).
25. The concentrated therapeutic phospholipid composition of claim 24, wherein the free fatty acid concentration of between about 10% (w/w) and about 15% (w/w).
26. The concentrated therapeutic phospholipid composition of claim 1, wherein the triglyceride concentration is between below about 5%.

27. The concentrated therapeutic phospholipid composition of claim 1, wherein the triglyceride concentration is about 0%.
28. The composition of claim 1, further comprising an antioxidant.
29. The composition of claim 28, wherein the antioxidant is selected from astaxanthin, a carotenoid, and a flavonoid.
30. The composition of claim 29, wherein the antioxidant is a carotenoid.
31. The composition of claim 30, wherein the carotenoid is pro-vitamin A.
32. The composition of claim 29, wherein the antioxidant is a flavonoid.
33. The composition of claim 32, wherein the flavonoid is selected from naringin, naringenin, hesperetin/kaempferol, rutin, luteolin, neohesperidin, quercetin.
34. The composition of claim 32, wherein the flavonoid is



35. The composition of claim 1, wherein the antioxidant is astaxanthin.
36. The composition of claim 35, wherein the concentration of astaxanthin is greater than 2000 mg/kg (w/w of composition).

37. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition comprises:

compounds of Formula I are at a concentration of about 66% (w/w (phospholipids/total composition));

a free fatty acid (FFA) concentration of less than ____% (w/w FFA/total composition); and

a triglyceride concentration of 0%.

38. The concentrated therapeutic phospholipid composition of claim 1, wherein the composition comprises:

compounds of Formula I are at a concentration of above 70% (w/w (phospholipids/total composition));

a free fatty acid (FFA) concentration of 0%; and

a triglyceride concentration of 0%.

39. The concentrated therapeutic phospholipid composition of claim 38, wherein the compounds of Formula I are at a concentration of about 90%.

40. A method of treating or preventing a cardiometabolic disorder / metabolic syndrome, the method comprising administering to a subject in need thereof a composition of claim 1.

41. The method of claim 40, wherein the cardiometabolic disorder / metabolic syndrome is selected from atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency, phospholipid deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy,

hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel and diabetic autonomic neuropathy.

42. A method of treating, preventing, or improving cognition and /or a cognitive disease, disorder or impairment (memory, concentration, learning (deficit)), the method comprising administering to a subject in need thereof a composition of claim 1.

43. The method of claim 42, wherein the cognitive disease, disorder or impairment is selected from Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), dyslexia, age-associated memory impairment and learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-Alzheimer's disease, autism, dystonias and Tourette syndrome, dementia, age related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well being, neurodegenerative disorders, hormonal disorders or any combinations thereof. In a specific embodiment, the cognitive disorder is memory impairment.

44. A method of inhibiting, preventing, or treating a neurodegenerative disorder, the method comprising administering to a subject in need thereof a composition of claim 1.

45. The method of claim 44 wherein the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, Lewy body dementia Basal ganglia–Huntington's disease, Parkinson's disease, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia Motor–amyotrophic lateral sclerosis, familial spastic paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia, amyotrophic lateral sclerosis, and familial spastic paraparesis.

1/37




FIGURE 1A




FIGURE 1B




FIGURE 1C


Circulating plasma Triglyceride concentration of C57BL/6 mice

FIGURE 2

Circulating plasma HDL-Cholesterol concentration of C57BL/6 mice

Mean	53.4	59.4	63.4	62.3
SEM	3.2	1.9	3.5	2.4
n	10	10	10	10




FIGURE 3

Circulating plasma *percentage* of HDL-Cholesterol in C57BL/6 mice

6/37

Mean	74.9	78.4	78.4	80.6
SEM	2.1	2.2	1.7	0.6
n	10	10	10	9


* $P < 0.05$

FIGURE 4

7/37

Circulating plasma LDL-Cholesterol concentration of C57BL/6 mice

Mean	13.3	11.1	11.2	9.6
SEM	1.2	1.4	1.0	0.7
n	10	10	10	9





FIGURE 5

Circulating plasma *percentage* of LDL-Cholesterol in C57BL/6 mice

Mean	18.9	14.5	14.1	12.2
SEM	1.8	1.7	1.4	0.5
n	10	10	10	9




* $P < 0.05$; ** $P < 0.01$

FIGURE 6

Circulating plasma NEFA concentration of C57BL/6 mice

Mean	2.92	2.65	2.93	2.63
SEM	0.10	0.06	0.12	0.09
n	10	9	9	9



* $P < 0.05$

FIGURE 7

10/37

Circulating plasma Glucose concentration of C57BL/6 mice

Mean	177.0	107.0	167.6	157.3
SEM	8.4	6.3	5.9	12.0
n	10	10	9	10

— ***


*** $P < 0.001$

FIGURE 8

11/37

Circulating plasma Phospholipid concentration of C57BL/6 mice

Mean	141.9	140.5	147.4	138.6
SEM	7.2	4.1	5.5	5.4
n	10	10	9	10




FIGURE 9

12/37

Circulating plasma ALT concentration of C57BL/6 mice

Mean	36.1	31.0	26.9	27.8
SEM	3.9	3.5	1.8	1.2
n	10	10	10	10





FIGURE 10

Liver Total Cholesterol concentration of C57BL/6 mice

Mean	23.1	23.3	25.8	24.1
SEM	0.8	0.6	0.3	0.8
n	10	10	9	10




** $P < 0.01$

FIGURE 11


Liver Triglyceride concentration of C57BL/6 mice

Mean	53.0	58.0	67.4	66.3
SEM	3.1	1.7	2.6	5.4
n	10	10	9	10



* $P < 0.05$; ** $P < 0.01$

FIGURE 12

Circulating plasma Triglyceride concentration of LDLr KO mice

** $P < 0.01$; *** $P < 0.001$

FIGURE 13

16/37

Circulating plasma HDL-Cholesterol concentration of LDLr KO mice

Mean	88.8	90.9	88.4	111.2
SEM	3.6	2.5	4.6	2.5
n	9	9	9	10



*** $P < 0.001$

FIGURE 14

Circulating plasma *percentage* of HDL-Cholesterol in LDLr KO mice

Mean	43.0	41.9	35.1	46.8
SEM	2.1	0.8	2.3	1.1
n	10	9	10	10



* $P < 0.05$

FIGURE 15

18/37

Liver Total Cholesterol concentration of LDLr KO mice

Mean	23.6	24.5	25.8	24.9
SEM	0.6	0.3	0.9	0.6
n	10	9	10	10





FIGURE 16

Liver Triglyceride concentration of LDLr KO mice

Mean	42.9	54.3	52.4	58.4
SEM	2.1	2.1	3.0	4.5
n	10	9	9	10




* $P < 0.05$; ** $P < 0.01$

FIGURE 17

20/37

**Circulating plasma Triglyceride concentration of ApoA-1 CETP
Tg mice**

Mean	53.0	19.3	43.2	43.0
SEM	12.9	2.8	11.7	8.2
n	9	9	9	8
	—————*			



* $P < 0.05$

FIGURE 18

Circulating plasma total cholesterol concentration of adult male SD, ZDF, SHR & JCR:LA rats





FIGURE 19

22/37


**Circulating plasma LDL/HDL concentration of adult male SD,
ZDF, SHR & JCR:LA rats**



#, 1 value removed

FIGURE 20


Circulating plasma HDL/LDL concentration of adult male SD, ZDF, SHR & JCR:LA rats



#, 1 value removed

FIGURE 21

**Circulating plasma total cholesterol/HDL concentration of adult male SD,
ZDF, SHR & JCR:LA rats**



#, 1 value removed

†, 2 values removed

FIGURE 22

Prothrombin Time of adult male SD, ZDF, SHR & JCR:LA rats




FIGURE 23

OGTT area under the curve data in ZDF male rats treated with Composition 3 for 90 days




FIGURE 24

OGTT area under the curve data in ZDF male rats treated with Composition 3 for 90 days




FIGURE 25

28/37

**OGTT area under the curve data in SD male rats treated with
Composition 3 for 90 days**

Mean	63.1	52.5	51.1	50.7	63.1	86.5	65.9	66.6
SEM	8.0	7.8	6.0	5.9	8.0	21.8	7.5	7.7
n	12	6	6	6	12	6	6	6




FIGURE 26

29/37

**OGTT area under the curve data in SD male rats treated with
Composition 3 for 90 days**




FIGURE 27

30/37

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 28

31/37

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 29

32/37

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 30

33/37

Effects of Composition 3 on Glucose Intolerance in male ZDF rats




FIGURE 31

Effects of Composition 3 on Glucose Intolerance in male ZDF rats




FIGURE 32

35/37


Effects of Composition 3 on Glucose Intolerance in male SD rats

FIGURE 33

36/37



Effects of Composition 3 on Glucose Intolerance in male SD rats

FIGURE 34

37/37

Comparative Effects of Composition 3 and Lovaza® on Omega-3 Index



	Δ OM3I/G OM3	Δ OM3I/G EPA	Δ OM3I/G DHA
Comp. 3 1g	62.85%	103.26%	160.62%
Lovaza 4g	30.65%	55.37%	68.65%
Δ Comp. 3 vs Lovaza	105.70%	86.49%	133.95%

FIGURE 35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001720

A. CLASSIFICATION OF SUBJECT MATTER IPC: A61K 31/683 (2006.01) , A61P 3/00 (2006.01) , A61P 9/00 (2006.01) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K 31/683 (2006.01) , A61K 31/685 (2006.01) , A61P 3/00 (2006.01) , A61P 9/00 (2006.01) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) EPOQUE, Canadian Patent Database, PubMed phospholipid, DHA, EPA, krill, squid, marine , fish supercritical fluid extraction, dyslipidemia, hyperlipidemia, hypertriglyceremia, diabetes		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X X	WO2008117062A1 (AKER BIOMARINE ASA) 02 -10-2008 (02 October 2008) tables 18B, 19B, 20B, 21, 22; tables 10, 13-15; tables 16 and 19C. examples 9, 12	1-5, 8-16, 23-27, 28-35 40-41
X X	WO03011873 A2 (NEPTUNE TECHNOLOGIES & BIORES et al) 13-02-2003 (13 February 2003) p.26, l. 3-6; table 5; example 1, Sample #804; p.30, l.1-7; table 5. example 3	1-3, 8-16, 23-24, 26, 28-35 42-45
A	WO02102394A2 (SAMPALIS) 27-12-2002 (27 December 2002) whole document	1-45
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 1 February 2010 (01-02-2001)		Date of mailing of the international search report 1 March 2011 (01-03-2011)
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476		Authorized officer Yong-Huang Chen (819) 956-4113

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☒ Claim Nos. : 40-45

because they relate to subject matter not required to be searched by this Authority, namely :

Claims 40-45 are directed to a method for treatment of the human or animal body by surgery or therapy, are not required to be searched nor is a written opinion required by this Authority. Regardless, this Authority has established a written opinion based on the alleged therapeutic effect or purpose/use of the product defined in claim 1.

2. ☐ Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. ☐ Claim Nos. :

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001720

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO0023546A1 (UNIV SHERBROOKE et al) 27-04-2000 (27 April 2000) table 14; tables 15, 16; tables 17, 18.	1-2, 8-16, 28-35
X	WO2008060163A1 (PRONOVA BIOPHARMA NORGE AS) 22-05-2008 (22 May 2008) tables 3-5; p.20, 1.5-9.	1-7, 8-16, 23-25, 28-35
X X	JP2215351A (MARUYAMA et al) 28-08-1990 (28 August 1990) p.327, right column, para.4; also JPO machine translation. example 2	1-16, 23-27, 37-39 42-45
X	JP2000060432A (NIPPON KAGAKU SHIRYO KK) 29-02-2000 (29 February 2000) para.[009]; example 1.	1-6, 8-20

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2010/001720

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2008117062A1	02 October 2008 (02-10-2008)	AU2008231570A1 CA2682068A1 EP2144618A1 US2008274203A1	02 October 2008 (02-10-2008) 02 October 2008 (02-10-2008) 20 January 2010 (20-01-2010) 06 November 2008 (06-11-2008)
WO03011873A2	13 February 2003 (13-02-2003)	AT363486T AU2002322233B2 CA2493888A1 DE60220415D1 DE60220415T2 DK1417211T3 EP1417211A2 EP1417211B1 ES2288193T3 PT1417211E US2004234587A1 WO03011873A3 WO03011873A8	15 June 2007 (15-06-2007) 23 October 2008 (23-10-2008) 13 February 2003 (13-02-2003) 12 July 2007 (12-07-2007) 14 February 2008 (14-02-2008) 08 October 2007 (08-10-2007) 12 May 2004 (12-05-2004) 30 May 2007 (30-05-2007) 01 January 2008 (01-01-2008) 28 August 2007 (28-08-2007) 25 November 2004 (25-11-2004) 01 May 2003 (01-05-2003) 07 August 2003 (07-08-2003)
WO02102394A2	27 December 2002 (27-12-2002)	AT419858T CA2449898A1 CN1516592A DE60230759D1 DK1406641T3 EP1406641A2 EP1406641B1 EP1997498A2 EP1997498A3 ES2321066T3 JP2004534800T JP2010090140A JP2010090141A NO20035618D0 PT1406641E US2004241249A1 US2007098808A1 WO02102394A3	15 January 2009 (15-01-2009) 27 December 2002 (27-12-2002) 28 July 2004 (28-07-2004) 26 February 2009 (26-02-2009) 04 May 2009 (04-05-2009) 14 April 2004 (14-04-2004) 07 January 2009 (07-01-2009) 03 December 2008 (03-12-2008) 03 June 2009 (03-06-2009) 02 June 2009 (02-06-2009) 18 November 2004 (18-11-2004) 22 April 2010 (22-04-2010) 22 April 2010 (22-04-2010) 16 December 2003 (16-12-2003) 15 April 2009 (15-04-2009) 02 December 2004 (02-12-2004) 03 May 2007 (03-05-2007) 10 April 2003 (10-04-2003)
WO0023546A1	27 April 2000 (27-04-2000)	AT391763T AU765464B2 AU6455299A BR9914699A BR9914699B1 CA2251265A1 CA2346979A1 CA2346979C CN1324394A CN1269940C DE69938504D1 DE69938504T2 DK1123368T3 EP1123368A1 EP1123368B1 ES2306527T3 HK1038765A1 JP2002527604T JP4181305B2 JP2008150586A NO20011915D0	15 April 2008 (15-04-2008) 18 September 2003 (18-09-2003) 08 May 2000 (08-05-2000) 10 July 2001 (10-07-2001) 01 December 2009 (01-12-2009) 21 April 2000 (21-04-2000) 27 April 2000 (27-04-2000) 07 July 2009 (07-07-2009) 28 November 2001 (28-11-2001) 16 August 2006 (16-08-2006) 21 May 2008 (21-05-2008) 10 June 2009 (10-06-2009) 04 August 2008 (04-08-2008) 16 August 2001 (16-08-2001) 09 April 2008 (09-04-2008) 01 November 2008 (01-11-2008) 12 September 2008 (12-09-2008) 27 August 2002 (27-08-2002) 12 November 2008 (12-11-2008) 03 July 2008 (03-07-2008) 18 April 2001 (18-04-2001)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2010/001720

		NO20011915A	21 June 2001 (21-06-2001)
		NO321481B1	15 May 2006 (15-05-2006)
		PL347396A1	08 April 2002 (08-04-2002)
		PL201771B1	29 May 2009 (29-05-2009)
		PT1123368E	18 July 2008 (18-07-2008)
		RU2236441C2	20 September 2004 (20-09-2004)
		UA75029C2	17 September 2001 (17-09-2001)
		US6800299B1	05 October 2004 (05-10-2004)
		ZA200103235A	20 June 2002 (20-06-2002)
WO2008060163A1	22 May 2008 (22-05-2008)	AR064250A1	25 March 2009 (25-03-2009)
		AU2007320183A1	22 May 2008 (22-05-2008)
		CA2669847A1	22 May 2008 (22-05-2008)
		CL32832007A1	23 May 2008 (23-05-2008)
		CN101652462A	17 February 2010 (17-02-2010)
		EP2094823A1	02 September 2009 (02-09-2009)
		EP2094823A4	02 February 2011 (02-02-2011)
		JP2010510208T	02 April 2010 (02-04-2010)
		KR20090085682A	07 August 2009 (07-08-2009)
		MX2009005227A	28 May 2009 (28-05-2009)
		NO20092310A	16 June 2009 (16-06-2009)
		PE10602008A1	08 September 2008 (08-09-2008)
		US2010143571A1	10 June 2010 (10-06-2010)
		WO2008060163A9	02 April 2009 (02-04-2009)
		ZA200904176A	25 August 2010 (25-08-2010)
JP2215351A	28 August 1990 (28-08-1990)	JP2215351A	28 August 1990 (28-08-1990)
		JP2909508B2	23 June 1999 (23-06-1999)
JP2000060432A	29 February 2000 (29-02-2000)	None	